Southern Capital Advisors LLC grew its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 36.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,277 shares of the company’s stock after acquiring an additional 2,482 shares during the period. Johnson & Johnson comprises about 1.1% of Southern Capital Advisors LLC’s investment portfolio, making the stock its 23rd biggest position. Southern Capital Advisors LLC’s holdings in Johnson & Johnson were worth $1,438,000 at the end of the most recent quarter.
Several other large investors have also made changes to their positions in the business. Moneta Group Investment Advisors LLC lifted its position in shares of Johnson & Johnson by 90,144.4% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after acquiring an additional 54,326,454 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Johnson & Johnson by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 47,958,583 shares of the company’s stock valued at $8,456,643,000 after acquiring an additional 294,671 shares in the last quarter. Morgan Stanley lifted its position in shares of Johnson & Johnson by 12.0% in the fourth quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after buying an additional 4,521,062 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Johnson & Johnson by 15.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock worth $5,171,919,000 after buying an additional 3,849,148 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth about $4,609,399,000. 67.57% of the stock is currently owned by hedge funds and other institutional investors.
Johnson & Johnson Trading Up 0.5 %
JNJ opened at $171.10 on Tuesday. The stock has a market cap of $444.64 billion, a price-to-earnings ratio of 34.64, a P/E/G ratio of 2.88 and a beta of 0.55. The stock’s 50 day moving average price is $160.60 and its 200-day moving average price is $161.20. Johnson & Johnson has a one year low of $150.11 and a one year high of $181.04. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.85 and a current ratio of 1.07.
Johnson & Johnson Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Investors of record on Monday, August 28th will be issued a $1.19 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.78%. Johnson & Johnson’s payout ratio is 96.36%.
Analyst Ratings Changes
A number of equities research analysts recently commented on JNJ shares. Stifel Nicolaus boosted their target price on Johnson & Johnson from $165.00 to $175.00 in a research report on Friday. StockNews.com started coverage on Johnson & Johnson in a research report on Thursday, May 18th. They issued a “strong-buy” rating on the stock. Credit Suisse Group boosted their target price on Johnson & Johnson from $170.00 to $175.00 and gave the stock a “neutral” rating in a research report on Friday. Morgan Stanley reissued an “equal weight” rating and set a $187.00 price objective on shares of Johnson & Johnson in a research note on Friday. Finally, Atlantic Securities reduced their price objective on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 19th. Eight equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $171.60.
Insider Activity at Johnson & Johnson
In related news, EVP Kathryn E. Wengel sold 12,465 shares of the business’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $160.00, for a total value of $1,994,400.00. Following the completion of the sale, the executive vice president now owns 65,934 shares in the company, valued at $10,549,440. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.20% of the stock is owned by company insiders.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- Which Wall Street Analysts are the Most Accurate?
- 3 Housing Stocks to Avoid as Interest Rates Rise
- How to Invest in Blue Chip Stocks
- AMC: Is a Big Squeeze in the Coming Attractions?
- What Are Dividend Champions? How to Invest in the Champions
- Rivian: A Roaring Rise Or Time To Cash Out?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
